The impact of European regulatory policies on psychotropic drug prescribing patterns

International Review of Psychiatry

Volumn 17, Issue 3, 2005, Pages 199-204

  Garattini, Silvio ^a   Bertele', Vittorio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; PSYCHOTROPIC AGENT; RISPERIDONE;

AGING; AGRANULOCYTOSIS; BEHAVIOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DIABETES MELLITUS; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; EUROPEAN UNION; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; LEUKOPENIA; NEUTROPENIA; POLICY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; WEIGHT GAIN;

EUROPE; HEALTH POLICY; HUMANS; MENTAL DISORDERS; MENTAL HEALTH SERVICES; PRESCRIPTIONS, DRUG; PSYCHIATRY; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 20444483321     PISSN: 09540261     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540260500072192     Document Type: Review

References (44)

1. Baldessarini, R. J., Cohen, B. M., & Teicher, M. H. (1998). Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives in General Psychiatry, 45, 79-91.
2. Barbui, C., Violante, A., & Garattini, S. (2000). Does placebo help establish equivalence in trials of new antidepressants? European Psychiatry, 15, 1-6.
3. Bertele', V., Torri, V., & Garattini, S. (1999). Inconclusive messages from equivalence trials in thrombolysis. Heart, 81, 675-676.
4. Blin, O., Azorin, J. M., & Bouhours, P. (1996). Antipsychotic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. Journal of Clinical Psychopharmacology, 16, 38-44.
5. Bollini, P. (1994). Antipsychotic drugs: is more worse? A meta analysis of the published randomised control trials. Psychological Medicine, 24, 307-316.
6. Breier, A., & Hamilton, S. H. (1999). Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biological Psychiatry, 45, 403-411.
7. Brodaty, H., Ames, D., Snowden, J., Woodward, M., Kirwan, J., Clarnette, R., et al. (2003). A randomized placebo controlled trial of risperidone for the treatment of aggression, agitation, and psychosis in dementia. Journal of Clinical Psychiatry, 64, 134-143.
8. Bronskill, S. E., Anderson, G. M., Sykora, K., Wodchis, W. P., Gill, S., Shulman, K. I., et al. (2004). Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. Journal of the American Geriatric Society, 52, 749-755.
9. Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001). Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry, 158, 518-526.
10. Chan, W., Lam, L. C., Choy, C. N., Leung, V. P., Li, S., & Chiu, H. F. (2001). A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. International Journal of Geriatric Psychiatry, 16, 1156-1162.
11. Chue, P. (2004). The assessment and management of antipsychotic- associated metabolic disturbances from a psychiatric perspective. Canadian Journal of Psychiatry, 49, 200-207.
12. Conley, R. R., Kelly, D. L., & Gale, E. A. (1998a). Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophrenia Research, 33, 95-101.
13. Conley, R. R., Tamminga, C. A., Bartko, J. J., et al. (1998b). Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. American Journal of Psychiatry, 155, 914-920
14. Copolov, D. L., Link, C. G., & Kowalcyk, B. (2000). A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychological Medicine, 30, 95-105.
15. Council of the European Communities. (1993). Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products. Official Journal of the European Communities No L 214 of 24/08/1993, p. 1
16. Davis, J. M., Barter, J. T., & Kane, J. M. (1989). Antipsychotic drugs. In H. J. Kaplan & B. J. Saddock (Eds), Comprehensive textbook of psychiatry (pp. 1591-1626, Fifth Edition). Baltimore: Williams and Wilkins.
17. De Deyn, P. P., Rabheru, K., Rasmussen, A., Bocksberger, J. P., Dautzenberg, P. L. J., Eriksson, S., et al. (1999). A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology, 53, 946-955.
18. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use Available from URL: http://pharmacos.eudra.org/ F2/review/ index.htm last accessed 9 September 2004.
19. EMEA. (2001). European Public Assessment Report on Zyprexa. http://www.emea.eu.int/humandocs/Humans/EPAR/Zyprexa/ Zyprexa.htm.
20. EMEA. (2004a). European Public Assessment Report on Abilify. http://www.emea.eu.int/humandocs/Humans/EPAR/ abilify/abilify.htm.
21. EMEA. (2004b). Public Statement on the safety of olanzapine (Zyprexa, Zyprexa Velotab) http://www.emea.eu.int/pdfs/ human/press/pus085604en.pdf accessed 14 July 2004.
22. Emsley, R., Turner, H. J., Schronen, J., Botha, K., Smit, R., & Oosthuizen, P. P. (2004). A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. Journal of Clinical Psychiatry, 65, 696-701.
23. Emsley, R. A., Buckley, P., Jones, A. M., & Greenwood, M. R. (2003). Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. Journal of Psychopharmacology, 17, 210-215.
24. Fontaine, K. R., Heo, M., Harrigan, E. P., Shear, C. L., Lakshminarayanan, M., Casey, D. E., et al. (2001). Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Research, 101, 277-288.
25. Garattini, S., Bertele', V., & Li Bassi, L. (2003). Light and shade in the proposed revision of the EU drugs regulatory legislation. Lancet, 361, 635-636.
26. Garattini, S., & Bertele', V. (2001). Adjusting regulatory rules to public health needs. Lancet, 358, 64-67.
27. Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal, 321, 1371-1376.
28. Katz, I., Jeste, D. V., Mintzer, J. E., Clyde, C., Napolitano, J., Brecher, M., et al. (1999). Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomized, double blind trial. Journal of Clinical Psychiatry, 60, 107-115.
29. Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S. S., Magder, L. S., Kreyenbuhl, J., et al. (2002). Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population-based nested case-control study. British Medical Journal, 325, 243-247.
30. Lee, P. E., Gill, S. S., Freedman, M., Bronskill, S. E., Hillmer, M. P., & Rochon, P. A. (2004). Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. British Medical Journal, 329, 75-79.
31. Leucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003). New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet, 361, 1581-1589.
32. Meltzer, H. Y. (2001). Treatment of suicidality in schizophrenia. Annals of the New York Academy of Science, 932, 44-58.
33. Osservatorio Nazionale sull'Impiego dei Medicinali (OsMed), Direzione Generale dei Farmaci e dei Dispositivi Medici, Ministero della Salute. L'uso dei farmaci in Italia. Rapporto nazionale anno 2003. Available from the URL http:// www.ministerosalute.it/medicinali/resources/documenti/osmed/ rapporti/osmed_2003.pdf
34. Peuskens, J., & Link, C. G. G. (1997). A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandinavica, 96, 265-273.
35. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. Available from URL: http:// pharmacos.eudra.org/F2/ review/index.htm last accessed 9 September 2004.
36. Rosenheck, R., Perlick, D., Bingham, S., Liu-Mares, W., Collins, J., Warren, S., et al. (2003). Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. Journal of the American Medical Association, 290, 2693-2702.
37. Rüther, E., & Blanke, J. (1988). Therapievergleich von Aminosultoprid (DAN 2163) und Perazin bei schizophrenen Patienten. In H. Helmchen, H. Hippius & R. Tölle (Eds), Therapie mit Neuroleptika Perazin (pp. 65-70). Stuttgart, New York: Georg Thieme Verlag.
38. Sanders, R. D., & Mossman, D. (1999). An open trial of olanzapine in patients with treatment-refractory psychoses. Journal of Clinical Psychopharmacology, 19, 62-66.
39. Straus, S. M. J. M., Bleumink, G. S., Dieleman, J. P., van der Lei, J., 't Jong, G. W., Kingma, J. H., et al. (2004). Antipsychotics and the risk of sudden cardiac death. Archives of Internal Medicine, 164, 1293-1297.
40. Street, J. S., Clark, W. S., Gannon, K. S., Cummings, J. L., Bymaster, F. P., Tamura, R. N., et al. (2000). Olanzapine treatment of psychotic and behavioural symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU study group. Archives in General Psychiatry, 57, 968-976.
41. The World Medical Association, Inc. (2000). The declaration of Helsinki. Ethical principles for medical research involving human subjects. Available from URL: www.wma.net.
42. Vanina, Y., Podolskaya, A., Sedky, K., Shahab, H., Siddiqui, A., Munshi, F., et al. (2002). Body weight changes associated with psychopharmacology. Psychiatric Services, 53, 842-847.
43. Wahlbeck, K., Cheine, M., & Essali, A. (2003). Clozapine for schizophrenia (Cochrane review). Cochrane Database System Reviews, 3, CDD51334.
44. Wahlbeck, K., Tuunainen, A., Ahokas, A., & Leucht, S. (2001). Dropout rates in randomised antipsychotic drug trials. Psychopharmacology, 155, 230-233.